Kestra Medical plans sale of 8,948 common shares

Kestra Medical Technologies, Ltd. (KMTS) reports a planned sale of up to 8,948 common shares through Merrill Lynch, to be sold on or after July 31, 2026 on NASDAQ, with an approximate aggregate market value of $202,259.77.

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. (KMTS) reports a planned sale of up to 8,948 common shares through Merrill Lynch, to be sold on or after July 31, 2026 on NASDAQ, with an approximate aggregate market value of $202,259.77. These shares were issued on July 17, 2026 as a performance stock issuance granted under the issuer’s equity compensation plan. The filing also lists recent sales by Brian Webster over the past three months, including 15,000 common shares on each of April 15, May 15, June 15, and July 15, 2026, and an additional 7,857 shares on July 30, 2026, for stated proceeds on each date.

Key Figures

Planned shares to be sold: 8,948 shares Aggregate market value of planned sale: $202,259.77 Grant date of performance stock: 07/17/2026 +5 more

8 metrics

Planned shares to be sold 8,948 shares Common stock to be sold on or after July 31, 2026 on NASDAQ

Aggregate market value of planned sale $202,259.77 Approximate market value of 8,948 common shares

Grant date of performance stock 07/17/2026 Performance Stock Issuance under issuer equity compensation plan

Sale on April 15, 2026 15,000 shares; $300,671.04 Common share sale by Brian Webster

Sale on May 15, 2026 15,000 shares; $314,329.85 Common share sale by Brian Webster

Sale on June 15, 2026 15,000 shares; $312,142.94 Common share sale by Brian Webster

Sale on July 15, 2026 15,000 shares; $336,609.41 Common share sale by Brian Webster

Sale on July 30, 2026 7,857 shares; $178,531.04 Common share sale by Brian Webster

Key Terms

Performance Stock Issuance, issuer equity compensation plan, Common Shares

3 terms

Performance Stock Issuance financial

"Common Stock | 07/17/2026 | Performance Stock Issuance |"

issuer equity compensation plan financial

"Granted as part of issuer equity compensation plan"

Common Shares financial

"Common Shares | 04/15/2026 | 15000 | 300671.04"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kestra Medical Technologies (KMTS) disclose in this Form 144 filing?

Kestra Medical Technologies discloses a planned sale of 8,948 common shares on NASDAQ with an estimated value of $202,259.77, plus prior monthly sales of KMTS common shares by Brian Webster over the preceding three months.

How many KMTS shares are planned to be sold and through which broker?

The filing reports a planned sale of 8,948 KMTS common shares to be executed through Merrill Lynch on or after July 31, 2026, with trading on NASDAQ and an estimated aggregate market value of $202,259.77.

What is the origin of the KMTS shares to be sold under this Form 144?

The 8,948 KMTS common shares were issued on July 17, 2026 as a Performance Stock Issuance granted under the company’s equity compensation plan, according to the disclosure in the securities information section.

What KMTS share sales has Brian Webster made in the last three months?

Brian Webster is listed as having sold 15,000 common shares on each of April 15, May 15, June 15, and July 15, 2026, plus 7,857 shares on July 30, 2026, each with stated total proceeds amounts.

On which exchange will the KMTS shares under this Form 144 be sold?

The planned 8,948 KMTS common shares covered by this notice are indicated for sale on the NASDAQ market, with Merrill Lynch listed as the broker handling the transaction for these common stock sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:26 PM Accepted by SEC EDGAR 07/31/2026 - 04:25 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001877188
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KESTRA MEDICAL TECHNOLOGIES, LTD.
SEC File Number	001-42549
Address of Issuer	3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WASHINGTON 98033
Phone	(425) 279-8002
Name of Person for Whose Account the Securities are To Be Sold	Webster Brian Daniel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St New York NY 10281	8948	202259.77	58602497	07/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/17/2026	Performance Stock Issuance	KESTRA MEDICAL TECHNOLOGIES, LTD.			8948	07/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	04/15/2026	15000	300671.04
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	05/15/2026	15000	314329.85
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 Common Shares WA 98033	Common Shares	06/15/2026	15000	312142.94
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	07/15/2026	15000	336609.41
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	07/30/2026	7857	178531.04

144: Remarks and Signature

Remarks
Date of Notice	07/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Brian Webster
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)